Compare Biogen Inc (BIIB) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Petróleo Brasileiro SA — how do they compare? Biogen Inc trades at $196.31 (market cap $28.34B), while Petróleo Brasileiro SA trades at $17.75 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 3.8× Biogen Inc's market cap, and Petróleo Brasileiro SA pays a 9.84% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PBR | |
|---|---|---|
Market Cap | $28.34B | $108.05B |
Sector | Health | Technology |
52-Week High | $216.63 | $22.03 |
52-Week Low | $122.68 | $11.54 |
Enterprise Value | $30.62B | $170.59B |
Dividend Yield | — | 9.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PBR trades at $17.88, up 3.23% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 5.71, net income margin of 21.47%, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments, supporting growth prospects amid positive analyst sentiment.
Outlook remains favorable with a consensus price target of $23.90, representing 33.6% upside potential. Key risks include oil price volatility and execution of new projects. The combination of low valuation, robust cash flow, and strategic expansion provides a compelling case for long-term investors, though market fluctuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
